Fulgent Genetics, Inc. $FLGT Shares Bought by UBS Group AG

UBS Group AG grew its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 288.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 83,559 shares of the company’s stock after acquiring an additional 62,070 shares during the quarter. UBS Group AG owned about 0.27% of Fulgent Genetics worth $2,195,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC boosted its holdings in shares of Fulgent Genetics by 69.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after acquiring an additional 548 shares during the period. Rhumbline Advisers boosted its holdings in shares of Fulgent Genetics by 2.4% during the second quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock valued at $659,000 after acquiring an additional 785 shares during the period. Peapod Lane Capital LLC boosted its holdings in shares of Fulgent Genetics by 0.7% during the fourth quarter. Peapod Lane Capital LLC now owns 165,781 shares of the company’s stock valued at $4,355,000 after acquiring an additional 1,202 shares during the period. Mackenzie Financial Corp boosted its holdings in shares of Fulgent Genetics by 11.2% during the third quarter. Mackenzie Financial Corp now owns 12,155 shares of the company’s stock valued at $275,000 after acquiring an additional 1,220 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Fulgent Genetics by 23.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,878 shares of the company’s stock valued at $286,000 after acquiring an additional 2,038 shares during the period. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Trading Up 1.3%

Shares of Fulgent Genetics stock opened at $17.90 on Thursday. The company’s 50-day moving average price is $15.99 and its two-hundred day moving average price is $22.00. Fulgent Genetics, Inc. has a 52 week low of $13.46 and a 52 week high of $31.04. The stock has a market cap of $508.36 million, a PE ratio of -7.49 and a beta of 0.88.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings results on Friday, February 27th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.02 by $0.14. Fulgent Genetics had a negative net margin of 23.04% and a negative return on equity of 3.24%. The firm had revenue of $83.34 million for the quarter, compared to analysts’ expectations of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. On average, equities analysts predict that Fulgent Genetics, Inc. will post -2.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Fulgent Genetics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Zacks Research downgraded shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $15.00 price objective (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $27.00.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.